Executive Profiles

Latest News


Bruno Strigini, CEO of Novartis Oncology, talks about the company’s pioneering path in cancer-starting with Gleveec and continuing with last year’s approval of the first-ever CAR-T cell therapy-touching on the related broader issues such as pricing and value and new innovations in cancer science.

Mary Lynne Hedley, president and COO of TESARO, talks to Pharm Exec about the company’s innovative approach to responsible drug development and commercialization, and how its theory of putting patients first is translated into practise.

Former critical care nurse Cynthia Schwalm, now executive vice president and president of North American commercial operations for Ipsen, speaks with Pharm Exec about her formula for successful team building internally-and the importance today of stepping outside of the C-suite and into the world of the patient.

Dr. Fumie Griego, the International Federation of Pharmaceutical Manufacturers and Associations’ new Assistant Director General, speaks with Pharm Exec about her mission to use IFPMA ’s international reach to find real and practical solutions to the most pressing global healthcare challenges.

Everyone’s talking value, but not everyone is willing to pin down the elusive concept. Pharm Exec talks with Steven Pearson, founder of the Institute for Clinical Effectiveness Review (ICER), about all things value-based.

The digital workplace is defined as a “business strategy to boost employee engagement and agility through a more consumerized work environment”. But what exactly does this mean for life sciences organizations? Michael Woodbridge explains.

For Bahija Jallal, chosen this year's Healthcare Businesswomen’s Association Woman of the Year, a passion for translational science has been the central guide in a career rise from cancer researcher to leading a big pharma biotech engine.

Six years in, Pharm Exec looks at the progress of the International Rare Diseases Research Consortium-an ambitious global effort focused on accelerating orphan disease diagnosis, and ultimately enabling better treatment options for these underserved patient populations.

Pharm Exec talks to Hugo Fry, Sanofi’s General Manager for the UK and General Manager for Sanofi Pasteur UK and Ireland, about his vision for the company and the vaccine space in these markets.